Biosensors can diagnose Parkinson's disease

The clinical manifestations of Parkinson's disease mainly include resting tremors, bradykinesia, muscle rigidity and posture gait disturbances, and patients may be associated with non-motor symptoms such as depression, constipation and sleep disorders. It is one of the problems that the medical community has been trying to overcome.

Recently, Chinese researchers have used quantum dots to construct a complex I biosensor that can be used to surprise Parkinson's disease for early diagnosis and monitoring of disease progression.

The current diagnosis is mainly based on clinical observations and cannot be accurately diagnosed by laboratory standard tests or biosensors. Therefore, it is difficult to diagnose in the early stage of Parkinson's disease, and it also becomes the biggest limit of disease diagnosis. This also makes it very urgent to develop a biosensor that can diagnose Parkinson's disease.

The researchers used quantum light dots (QDs), tiny light-emitting crystals, capable of absorbing broad spectrum, narrow emission spectrum, and resistance to photobleaching. They used ubiquinone-terminated ubiquinone bonds with different alkyl intervals. Disulphides) constructed a complex I biosensor.

The main cause of sporadic Parkinson's disease may be due to the inhibition of NADH: ubiquinone oxidoreductase (complex I) in mitochondria. The abnormality of complex I causes dopamine neurons to be suppressed, leading to the main clinical symptoms of Parkinson's disease. Therefore, early diagnosis of Parkinson's disease can start with the loss of complex I activity. Complex I biosensors can monitor different complex I levels in SH-SY5Y cells and can therefore be used as an important early diagnosis of Parkinson's disease.